Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $412,356.93 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93. Following the transaction, the chief executive officer now owns 418,519 shares of the company’s stock, valued at approximately $12,735,533.17. This trade represents a 3.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS opened at $30.00 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The business’s 50-day moving average price is $32.08 and its two-hundred day moving average price is $33.18. The company has a market capitalization of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.17) EPS. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Mizuho reduced their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Wells Fargo & Company dropped their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Citigroup reduced their price objective on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Finally, Robert W. Baird reduced their price target on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D boosted its holdings in Apellis Pharmaceuticals by 6.6% in the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after acquiring an additional 39,931 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares during the last quarter. Xponance Inc. raised its stake in shares of Apellis Pharmaceuticals by 7.6% in the 2nd quarter. Xponance Inc. now owns 13,773 shares of the company’s stock valued at $528,000 after acquiring an additional 968 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Apellis Pharmaceuticals in the 2nd quarter worth approximately $2,350,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).